2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 1
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Lymphoma, T-Cell, Peripheral
2
Hodgkin Disease
2
Recurrence
1
Interventions
Cisplatin
1514
Carboplatin
1416
Cyclophosphamide
1359
Gemcitabine
1235
Bevacizumab
1223
Paclitaxel
1210
Radiotherapy
1173
Docetaxel
1079
pembrolizumab
1026
Oxaliplatin
934
Capecitabine
898
Fluorouracil
832
Rituximab
729
Doxorubicin
683
Nivolumab
679
Dexamethasone
665
Etoposide
660
Irinotecan
622
Leucovorin
574
Pemetrexed
508
Drug Therapy
491
Cetuximab
481
Trastuzumab
467
Cytarabine
466
Magnetic Resonance Spectroscopy
457
Filgrastim
446
Prednisone
432
Lenalidomide
409
Specimen Handling
407
Temozolomide
400
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2
×
AFM13
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts
NCT04101331
2024-11-05
REDIRECT
Affimed GmbH
Phase 2
Completed
108 enrolled
24 charts
NCT02321592
2020-11-13
GHSG-AFM13
University of Cologne
Phase 2
Completed
23 enrolled